Syros Pharmaceuticals, Inc. engages in the development of gene control therapies for cancer and diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 68 full-time employees. The company went IPO on 2016-06-30. The firm is actively engaged in the voluntary delisting process. The firm was previously engaged in developing new standards of care for the frontline treatment of patients with hematologic malignancies.

Industry: Pharmaceutical Preparations Peers: Astria Therapeutics, Inc. Greenwich Lifesciences Inc INmune Bio Inc Nuvectis Pharma Inc Olema Pharmaceuticals Inc PepGen Inc Praxis Precision Medicines Inc Shattuck Labs Inc XBiotech Inc